← board
RLYB
Rallybiodistress 5/10 · elevated risk$16.83+1%today0% from 52w high
Cardiovascular 1Immunology / Inflammation 1
Lead: complement-driven diseases
Revenue
pre-revenue
Liquidity
$47M
Runway
1.0 yrs
Shares 1y
-87%
Price & events
+212.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.3%
1D
+5.5%
1W
+7.2%
1M
+98.0%
3M
+213.1%
6M
+297.7%
1Y
+57.0%
2Y
—
5Y
-85.1%
All
Overview
- Market Cap
- $89.17M
- Volume
- 1.30K
- 52 Week Range
- $3.25 – $16.91
- Total Shares
- 5.30M
- Float Shares
- 785.18K
- Short %
- 8.33%
- % Held by Insiders
- 4.22%
- % Held by Institutions
- 107.48%
- RVOL
- 0.03x
- Beta
- -0.89
Pipeline stages · 2 programs
Anti-(integrin beta-3) human monoclonal antibody
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
RLYB116 for Injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-02-09 | Phase 1 | RLYB116 for Injection | Hematologic Diseases, Autoimmune Diseases | 16 | completed |
| 2025-10-01 | Phase 2 | Anti-(integrin beta-3) human monoclonal antibody | Fetal and Neonatal Alloimmune Thrombocytopenia | 1 | terminated |
Catalyst news & presentations · 7
- 2026Guided 40%trial initiationsecondaryPhase 1REV102 · Initiation of Phase 1 studySEC 8-K
- 2026-05-31partnershipMerger agreement with Avenzo TherapeuticsSEC 8-K
- fourth quarter of 2025readoutRLYB116 · Cohort 2 data from confirmatory PK/PD studySEC 8-K
- third quarter of 2025readoutRLYB116 · Cohort 1 data from confirmatory PK/PD studySEC 8-K
- 2025-07-08partnershipENPP1 JV compound · Sold 50% interest in ENPP1 JV to Recursion for cash, shares, milestones, and royalties.SEC 8-K
- second quarter of 2025trial initiationsecondaryRLYB116 · Confirmatory PK/PD study initiationSEC 8-K
- 2025-04-08trial discontinuedRLYB212 · RLYB212 program discontinued due to PK resultsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-04-15Jones TradingBuy → Hold
- 2025-04-09HC Wainwright & Co.Buy → Neutral
- 2025-03-17HC Wainwright & Co.Buy
- 2025-02-12HC Wainwright & Co.Buy
- 2025-01-13HC Wainwright & Co.Buy
- 2024-12-03HC Wainwright & Co.Buy
Competitors — complement-driven diseases
- none identified
Recent news
- 2026-07-21RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - Stocktwits
- 2026-07-05Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock By Investing.com - Investing.com Nigeria
- 2026-06-05ADAR1, Daniel Schneeberger disclose 17.5% stake in Rallybio (RLYB) - Stock Titan
- 2026-06-01Rallybio to Merge With Avenzo in Stock Deal; $215 Million Financing Planned - TradingView
- 2026-06-01After failed deal, Rallybio announces new merger; New Haven HQ to close - Hartford Business Journal
- 2026-05-28RLYB - Finviz
- 2026-05-15Adar1 Capital Management buys $1.11m of Rallybio (RLYB) stock - Investing.com
- 2026-05-13Adar1 capital, manager Daniel Schneeberger buy $711,054 Rallybio stock. - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.